Sihuan Pharmaceutical Acquires Ambest Pharma China For $160 Million

Sihuan Pharma, headquartered in Beijing, will pay $160 million to acquire Ambest Pharma of China, a maker of large volume injection products. Ambest offers saline (sodium chloride) injections along with TCM and standard chemical products. Since its $742 million Hong Kong IPO in 2010, Sihuan has been an active participant in China pharma M&A while also developing a robust R&D pipeline. The company invests as much as 10% of its revenues in R&D, and at one point two years ago, Sihuan claimed to have a pipeline of 14 novel China Class 1.1 drugs in development.